Search
Lundbeck CEO Charl van Zyl describes the rationale for today's $2.6 billion acquisition of Longboard Pharma
He explains the market opportunity he sees for Bexicaserin and the data that made him comfortable to pull the trigger on the deal today...
Oct 14, 2024
Ghent based Confo Therapeutics is leveraging GPCR expertise as a discovery engine - multiple partners have already signed on to the science
CEO Cedric Ververken walks us through what separates Confo from other GPCR developers, and discusses pipeline programs in pain, obesity,...
Oct 14, 2024
Copenhagen based FluoGuide is working to light up tumors for surgeons by guiding fluorescent molecules to uPAR - a target that has been studied widely in Scandinavia
CEO Morten Albrechtsen describes the rational for this target for this purpose and how they FluoGuide has designed its fluorescent agent....
Oct 11, 2024
IO Biotech is developing a cancer vaccine that targets both the tumor and its microenvironment - a pivotal readout is coming in the first half of next year
Founder and CEO Mai-Britt Zocca explains the rationale for this dual focus and walks us through the lead program that targets PD-L1 and...
Oct 11, 2024
The co-founder of the startup Ousia Pharma describes working from Copenhagen's BioInnovation Institute on his company's next-generation enhancer to GLPs
Anders Bue Klein describes how the BI has made it easier for founders like him to take work from university and turn it into a company....
Oct 10, 2024
The BioInnovation Institute in Copenhagen was founded by the Novo Nordisk Foundation to help turn local ideas in life sciences into commercial enterprises
Chief International Officer Bobby Soni describes all the different ways that BI supports entrepreneurs such as grants, facilities,...
Oct 10, 2024
A deep-dive discussion on obesity drug development with Zealand Pharma's CEO Adam Steensberg
He highlights Zealand’s three different approaches to obesity: glucagon/GLP-1, GLP-1/GLP-2, and an amylin analog. Plus, he shares his...
Oct 10, 2024
Biotech veteran Hans Schikan gives an overview of the Netherlands' life sciences scene
The former CEO of Prosensa and current contributor to numerous boards highlights the past and current successes that have made this region a
Oct 9, 2024
Ronald Plasterk introduces us to his new company, Tzu Cancer Therapeutics, and the importance of focusing on circulating tumor cells
After selling his previous company, Frame Therapeutics, to CureVac, the Amsterdam based molecular biologist and entrepreneur wants to...
Oct 9, 2024
Leyden Labs is developing antibody-based nasal sprays that aim to stop viruses like flu and covid at the mucosa and with broad protection
Co-founder and CEO Koenraad Wiedhaup describes the shortcomings of today’s vaccines and why the company has chosen this unique approach....
Oct 9, 2024
Edinburgh HQ'd Resolution Therapeutics announced a £63.5M series B this month to advance its pro-regenerative macrophage therapy into further end-stage liver disease studies
CEO Amir Hefni describes how this autologous product is designed to work, the investments Resolution has made in its manufacturing...
Oct 8, 2024
Leiden based ProQR invented the idea of using RNA oligonucleotides to induce ADAR to edit RNA over 10 years ago - the first programs are scheduled to enter the clinic soon
Founder and CEO Daniel de Boer describes ProQR's history in Leiden and why it is an ideal spot for a biotech company to be based. Plus,...
Oct 8, 2024
George Church on founder led companies, synthetic biology technologies, the future, and more
Dan Mandell, Co-Founder and CEO of GRO Biosciences, interviews professor Church about the Genomically Recoded Organisms (GRO) platform...
Oct 7, 2024
BioVenture VoiCes Episode 3: Time BioVentures' D.A. Wallach
D.A. Wallach describes how he went from music to healthcare/biotech investing, and the similarities he sees between the two industries....
Oct 6, 2024
Oxford, UK based Enara Bio announced a $32.5M series B to further its work developing TCR based therapies that target antigens found in the 'dark genome'
President & CEO Kevin Pojasek describes how the company searches for these novel cancer-specific antigens that are from areas of the...
Oct 4, 2024
Mizuho senior analyst Graig Suvannavejh joins BiotechTV for Analyst Thursdays from Kendall Square
He shares his take on biotech and discusses Terns, Novo Nordisk, Corbus, Harmony Bio, IDEAYA, and Adverum.
Oct 3, 2024
Gene therapy experts TJ Cradick and Kate Excoffon discuss using AAV gene therapy for cystic fibrosis
Dr. Excoffon describes her academic experience that led her to the field and Spirovant Sciences, discusses interesting data from last...
Oct 3, 2024
Vedanta Biosciences founder and CEO Bernat Olle shares an expert take on microbiome drug development
He describes how Vedanta is isolating specific bacterial strains and using them as a defined composition for its medicines, and why he...
Oct 3, 2024
Flagship's ProFound Therapeutics is searching for proteins for use as therapeutics and targets beyond those found in the traditional protein coding regions of DNA
CEO John Lepore, who was previously head of research at GSK, describes how the company is screening all proteins that are made by...
Oct 2, 2024
Vor Bio is trying to help AML patients who receive a stem cell transplant to be more amenable to follow-on therapies - they just had key PoC data
President and CEO Robert Ang describes how Vor knocks out CD33 in transplant cells before they are administered so that patients can...
Oct 2, 2024
.png){kind=logo}
